Blog, News and Events

30 April 2024

Exhibition at the American Society of Cell & Gene Therapy 2024 Meeting

The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the premier event for researchers in gene and cell therapy. The meeting will cover a range of topics from cutting-edge studies in cell and gene therapy, viral hepatitis, liver toxicity, MASH/MAFLD, and more. PhoenixBio is excited to be sponsoring a booth and attending ASGCT's 27th Annual Meeting in person at the Baltimore Convention Center in Baltimore, MD on May 7th - 11th, 2024. Meet with our team at Booth #1917 to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Events

26 March 2024

Newsweek Feature: Pioneering Drug Development with Human Liver Models

Breaking News: Revolutionizing Pharmaceutical Innovation with Japan’s PhoenixBio In the realm of pharmaceutical innovation, a new dawn arises with Japan's PhoenixBio leading the charge. With a groundbreaking article recently published, PhoenixBio introduces cutting-edge human liver models boasting an astonishing 90% and higher human hepatocyte composition, redefining drug testing worldwide while upholding the highest ethical standards.

12 November 2023

American Association for the Study of Liver Diseases 2023 Meeting

Get ready to join the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease! The Liver Meeting will cover a range of topics from cutting-edge studies in viral hepatitis, liver toxicity, gene therapy/editing, MASH/MAFLD, and more. PhoenixBio is delighted to be attending The Liver Meeting in person at the Hynes Convention Center in Boston, MA on November 11th - 13th, 2023. Meet with our team at Booth #1002 to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Events

13 September 2023

2023 International HBV Meeting

PhoenixBio is delighted to be attending the International HBV Meeting in person at the Kobe International Conference Center in Kobe, Japan on September 19th - 23rd, 2023. We'll be sponsoring the conference and providing talks on preclinical models. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.

Events

13 September 2023

EuroTox 2023 Meeting

PhoenixBio is delighted to be attending the 57th Congress of the European Toxicologists and European Societies of Toxicology in person at the Ljubljana Exhibition and Convention Centre in Ljubljana, Slovenia on September 10th - 13th, 2023. We'll be exhibiting our products & services at booth #35. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you with drug metabolism, pharmacokinetic, and toxicology research.

Exhibition, Events

21 August 2023

PXB-mouse: Overcoming species-to-species differences to accurately predict hepatotoxicity in therapeutic development

It is estimated that 40% of drug candidates have failed to make it to market because of toxicity.¹ One of the most common adverse drug reactions is drug-induced liver injury (DILI), whereby patients experience acute illness, often with symptoms similar to hepatitis and cholestasis. Today, DILI is the leading cause of drug candidate failure and post-market withdrawals.² The high incidence of DILI in clinical trials, and even post-market events, is partly due to the use of conventional animal models at preclinical stages. Conventional models are notoriously poor predictors of efficacy and toxicity in the liver, due to species-to-species variation. In contrast, the PXB-mouse® model, with its humanized liver, provides a highly predictive model of human physiology and human-specific hepatotoxicity, allowing for more accurate prediction of human outcomes, and, therefore, aiding the smooth progression of new therapeutics into the clinic.

PXB-mouse, News, Blog

7 August 2023

Setting up HBV studies for human translational success

Hepatitis B is a serious and globally prevalent disease with 296 million people worldwide living with chronic hepatitis B virus (HBV) infections. Recent advances in HBV therapeutics have made infection a treatable disease, but they only disrupt certain areas of the HBV lifecycle. As a result, if the therapeutics are withdrawn, patients can relapse. What’s more, long-term use can cause antiviral resistance. To cure the disease, therapeutics need to address every stage of the HBV lifecycle, providing both seroclearance of the hepatitis B surface antigen (HBsAg) and silencing of the genomically integrated HBV DNA. However, investment in this space carries considerable risk as developers struggle to move treatments from animal models to human studies. Notably, human responses to HBV therapies are notoriously difficult to predict and traditional animal models translate poorly to the human environment, causing significant delays, as well as safety, cost, and efficacy concerns.

PXB-mouse, News, Blog

24 July 2023

Selecting the best model for preclinical hepatitis studies

How can humanized liver models provide accurate efficacy measurements at each stage of the viral lifecycle? Hepatitis B is a serious global health threat. Around 1.5 million hepatitis B virus (HBV) infections were identified in 2019 alone and around 296 million people are thought to be living with the chronic disease.¹ Researchers are now targeting previously unexplored areas of the viral lifecycle to get closer to developing a complete cure.

PXB-mouse, News, Blog